Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test
Co-Diagnostics (Nasdaq: CODX) said it submitted a Dual 510(k) premarket notification with a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro instrument. The filing follows clinical studies of 1,400 symptomatic patients and analytical work across 27 studies and 10,000+ PCR runs. If granted, the CLIA waiver would enable decentralized point-of-care use; the platform is not yet for sale.
How this was made
The 30-second read
Why it matters
If FDA accepts and clears the 510(k) and grants the concurrent CLIA Waiver by Application, the test could be used in decentralized waived point-of-care settings, expanding access beyond traditional labs.
Market read
This is a concrete regulatory-pathway step with supporting study enrollment and analytical run counts, but the market will still wait for FDA acceptance and clearance/waiver decisions.
What to watch
Investors may be underweighting manufacturing scale-up, instrument/consumable adoption risk, and the possibility that any CLIA waiver is narrower than the company’s commercialization vision.
Background
Co-Diagnostics is advancing its PCR platform toward decentralized point-of-care use, with this filing tied to a specific upper respiratory multiplex assay (Flu A/B & RSV).
Ticker impact
Co-Diagnostics submitted a Dual 510(k) and concurrent CLIA Waiver by Application for its Flu A/B & RSV multiplex test on the PCR Pro instrument.
Near-term reaction likely modest unless FDA acceptance/clearance timing is clarified; upside skew if investors view CLIA-waived PCR as a scalable channel.
The article discloses a fresh FDA filing milestone plus supporting clinical/analytical study scope, but it does not provide FDA feedback, acceptance, or clearance, which are the key catalysts for valuation re-rating.
Market effects
Supports the broader narrative of expanding decentralized molecular testing via CLIA-waived PCR platforms, potentially increasing competitive focus on workflow and instrument ecosystems.
Primarily U.S. regulatory and reimbursement pathway implications for point-of-care respiratory testing.
Limited direct global impact until FDA clearance enables broader adoption and data supports expansion to additional assays/markets.
Counterpoint
A 510(k) submission alone may not change near-term revenue expectations because FDA can request additional data or impose limitations on intended use.
Key entities
- companyCo-Diagnostics, Inc.
Nasdaq-listed molecular diagnostics company submitting the Dual 510(k) and concurrent CLIA Waiver by Application for its Flu A/B & RSV multiplex test.
- regulatorU.S. Food and Drug Administration (FDA)
Reviews the 510(k) premarket notification and determines clearance and any limitations.
- regulatory_pathwayCLIA Waiver by Application
If granted, would enable use of the test in decentralized waived point-of-care settings.
